Valuation
- Market cap
- 16,540,000
- Revenue TTM
- $0
- Net income TTM
- $-18,210,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 313,800
- Avg volume
- 258,658
- Day's range
- $1.13 – $1.28
- Shares out
- 13,339,000
- Stochastic %K
- 28%
- Beta
- 0.38
- Analysts
- Strong Sell
- Price target
- $9.25
Company profile
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for...
Show more
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 713 489 8654
- Website
- https://tvarditherapeutics.com
- Address
- 3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States
Latest news
No headlines yet.
